Global law firm Reed Smith announced today that it advised RadNet, a US leader in the provision of outpatient diagnostic imaging services, on its acquisition of a 75% interest in London-based Heart & Lung Imaging Limited (HLH).
Stethoscope on a clipboard

HLH, a London-Based Teleradiology Network Focused on Lung Cancer Screening, was founded to improve lung cancer outcomes through early detection and accurate diagnosis. HLH’s unique United Kingdom-wide network of over 70 expert cardiothoracic radiologists provides specialist reporting services for the UK’s National Health Service (NHS). Of particular note, HLH has established itself as the leading provider of lung cancer screening reporting services to the NHS England Targeted Lung Health Check (TLHC) program.

As part of the TLHC roll-out, HLH already utilizes software from RadNet’s Netherlands-based wholly-owned subsidiary, Aidence, including pulmonary nodule management and lung cancer Artificial Intelligence (AI) screening tools. The TLHC program mandates the combined use of AI and expert radiologist interpretation as a mechanism to ensure accurate diagnosis, to reduce unnecessary patient call-backs and to determine malignancy. HLH will further team up with Aidence to provide services and expertise to continue to enhance Aidence’s future AI offerings.

The trans-Atlantic team at Reed Smith advising RadNet was led by Global Corporate Group partners Milan Thakker and Lynwood Reinhardt, who were principally supported by senior associate Victoria Bryden and associate Brooke Dorris respectively. The Reed Smith team also included partners Caspar Fox, David Ashmore, Wim Vandenberghe, Marjorie Holmes, Philip Thomas, Carolyn Pepper, Will Sutton and Brigid North, as well as associates Harrison Stimson, Anna Goodman-Jones, Crystal Okwurionu, Vaibhav Adlakha and Jonathan Andrews.

Commenting on the closing, London partner Thakker said: “We are delighted to have supported the RadNet team on this strategically important investment, which we expect will lead to improvements in the early detection rate and outcomes for lung cancer patients across the United Kingdom. We wish both HLH and its impressive founder team all the best as they enter into this exciting and transformative new partnership with RadNet.”

Dr. Howard Berger, Chairman and Chief Executive Officer of RadNet, noted: “This is a very exciting transaction that furthers our objective of launching widespread population health screening programs. Lung cancer can be treated much more effectively and at a significantly lower cost if diagnosed earlier. The NHS has made a commitment to fighting lung cancer and addressing the health of its population. Through deploying RadNet’s industry-leading Aidence AI algorithms combined with HLH’s world-class cardiothoracic radiologist interpretation, we have an offering that can address the challenges of creating a cost-effective population health screening program in the UK and ultimately in the United States and other countries.”